凉血清营颗粒对Ⅰ型变态反应的影响

目的:研究凉血清营颗粒对Ⅰ型变态反应的影响.方法:用天花粉蛋白所致小鼠速发型超敏反应及大鼠同种异体被动超敏反应(PCA)观察对Ⅰ型变态反应的影响;用化合物48/80所致小鼠过敏性休克死亡及大鼠颅骨肥大细胞模型观察对肥大细胞脱颗粒的影响;用组织胺所致小鼠皮肤毛细血管通透性亢进试验观察对组织胺的直接对抗作用.结果:凉血清营颗粒能一定程度拮抗天花粉蛋白所致小鼠过敏性休克及大鼠PCA,并能明显抑制化合物48/80及天花粉蛋白所致腹腔或骨膜肥大细胞脱颗粒,还能明显对抗组织胺所致毛细血管通透性亢进.结论:凉血清营颗粒具有显著的抗Ⅰ型变态反应作用,此作用可能是其能抑制IgE生成、肥大细胞脱颗粒及直接拮抗组织胺作用的综合效果.     

防滑钢针及Y形酒精滴管在下肢骨牵引病人中的应用

为探讨自制防滑钢针及Y形酒精滴管在下肢骨牵引病人中的应用效果.选择需行下肢骨牵引的病人100例,随机分成实验组和对照组各50例.实验组采用自制防滑钢针及Y形酒精滴管;对照组采用传统钢针及酒精点滴.观察2组病人钢针滑动、压疮、针道感染情况.结果实验组钢针牵引滑动率显著低于对照组(P＜0.01).针道感染率明显低于对照组(P＜0.01).表明应用自制防滑钢针及Y形酒精滴管效果确切,经济实用,使用方便,可有效避免并发症的发生.     

Treatment of 116 cases of facial pigmented spots by auricular needle-embedding method

以耳穴子宫、神门、内分泌、肺为主穴,根据辨证选取配穴,埋针治疗面部色素斑患者116例,全部治愈.     

奥沙利铂联合氟尿嘧啶和亚叶酸钙治疗晚期大肠癌

目的：研究奥沙利铂、氟尿嘧啶、亚叶酸钙联合治疗晚期大肠癌的疗效和毒性反应，并将该方案和氟尿嘧啶与亚叶酸钙联合治疗方案相比较。方法：经病理确诊的晚期大肠癌83例分为以下两组：治疗组行奥沙利铂(oxalipatin)130mg／m^2静脉滴注，第1天给药：氟尿嘧啶(5-FU)425mg／m^2静脉滴注，第1-5天给药；亚叶酸钙(CF)100mg／m^2静脉滴注，第1～5天给药；每3周重复。对照组行氟尿嘧啶(5-FU)42h5mg／m^2静脉滴注,第1～5天给药；亚叶酸钙(CF)100mg／m^2。静脉滴注，第1-5天给药；每3周重复。每例患者至少完成两个周期。结果：治疗组有效率为46．5％，常见的毒性反应为神经毒性；对照组有效率为17．5％，与治疗组差别有统计学意义，未见神经毒性，其他毒性与治疗组无统计学差异。结论：奥沙利铂联合氟尿嘧啶和亚叶酸钙治疗晚期大肠癌,患者对其耐受良好，毒副反应较轻，疗效高于氟尿嘧啶加亚叶酸钙方案。     

Ⅲb期宫颈癌的放射治疗并化疗疗效观察

目的:观察放射治疗并同期化疗Ⅲb期宫颈癌的疗效及不良反应.方法:对59例Ⅲb期宫颈癌患者随机分为放射治疗 化疗组(放、化组)和单纯放射治疗组(单放组).两组放疗方案相同,化疗与放疗同时进行.结果:近期有效率放、化组为100%,单放组为92.3%,两组无明显差异(P＞0.05);5年生存率放、化组为69.7%,单放组为42.3%,两组有显著差异(P＜0.05);恶心、呕吐消化道反应和白细胞降低率放、化组较单放组明显高(P＜0.01 P＜0.05),放射性直肠炎、膀胱炎两组无差异(P＞0.05);远处转移率单放组明显高(P＜0.05).结论:放射治疗同时化疗可提高局部控制率及5年生存率,减少远处转移率.不良反应经对症治疗后,症状减轻或消失.     

胃肠道交界性病变/肿瘤和相关病变的临床病理特点及其治疗原则

交界性病变／交界性肿瘤是目前诊断病理面临的最大难题之一。病理和临床医师应正确认识胃肠道的一些交界性病变／交界性肿瘤及相关病变如胃肠道间质瘤、胃肠道淋巴组织增生和粘膜相关淋巴组织淋巴瘤、免疫增生性小肠病、胃肠道腺瘤和阑尾类癌。     

18例大肠癌肝转移高强度聚焦超声治疗的临床观察

目的:研究高强度聚焦超声(HIFU)治疗大肠癌肝转移病灶的安全性和有效性.方法:18例大肠癌术后肝转移患者31个病灶行HIFU治疗,观察患者生命体征、主要脏器功能、影像学检查(CT或MRI等)、并发症和肿瘤转归的情况.结果:所有患者生命体征平稳,肝、肾功能正常,平均随访16.1个月(6～38个月),失访2例,生存13例,12、18个月生存率分别为83.3%和66.7%,中位生存期16个月;随访25个病灶中,17个肿瘤块缩小超过50%,有5例出现新的转移灶,8例出现皮肤浅Ⅱ度烧伤.结论:HIFU治疗是一种安全、有效和非侵入性治疗大肠癌肝转移病灶的手段.     

Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: results from the Shanghai Breast Cancer Study and meta-analysis.

PURPOSE: We studied the relation of breast cancer to common deletion mutations in GSTM1 and GSTT1 and the functional Ile(105)Val polymorphism in GSTP1 in a large, population-based case-control study conducted in China and performed a meta-analysis to summarize the literature. EXPERIMENTAL DESIGN: In the case-control study, a total of 1144 breast cancer cases and 1221 community controls were genotyped for GSTM1, GSTP1, and GSTT1 using PCR-based methods. Associations of genotypes and breast cancer were evaluated in logistic regression models. Meta-analysis odds ratios (ORs) were estimated using a fixed effects model. RESULTS: In the case-control study, associations were null for GSTM1 [age-adjusted OR 0.97, 95% confidence interval (CI): 0.82-1.14] and GSTT1 (OR 0.97, 95% CI: 0.83-1.15). A significant increase in risk was observed among homozygotes for the variant Ile(105)Val polymorphism (OR 1.92, 95% CI: 1.21-3.04). No combined effects of GSTM1, GSTP1, and GSTT1 genotypes or interactions with potential effect modifiers were detected. All results were similar in pre- and postmenopausal women and for early versus advanced stage breast cancer. The meta-analysis, based predominantly on Caucasian women, supported null results for the homozygous deletion variant in GSTM1 (summary OR 1.05; combining 19 studies) and GSTT1 (summary OR 1.11; 15 studies). Meta-analysis results for the homozygous GSTP1 variant indicated no overall association (summary OR 1.04; 10 studies), although results varied significantly across studies (P = 0.009). CONCLUSIONS: This large case-control study provides strong support for earlier studies showing no overall association of the GSTM1 and GSTT1 deletion polymorphisms with breast cancer risk. The GSTP1 variant may be relevant to breast cancer risk in Asian populations.     

DIAGNOSTIC IMPLICATIONS OF IMMUNOHISTOCHEMICAL MARKERS IN UTERINE SMOOTH MUSCLE TUMORS

Objective: To evaluate the diagnostic implications of immunohistochemieal markers in uterine smooth muscle tumors. Methods: Formalin-fixed paraffin-embedded tissue blocks were selected from 17 uterine leiomyosarcomas, 40 uterine unusual leiomyomas and 25 uterine usual leiomyomas. Utilizing immunohistochemical techniques with antigen retrieval, serial sections of each tumor for immunoreactivity with myogenic markers, ovarian steroid receptors, CD44v3, proliferating cell nuclear antigen and mast cells were assessed. Results: Although the myogenic markers and CD44v3 showed less frequent positivity in uterine leiomyosarcomas than those in unusual leiomyomas,they were not reliable markers for differentiating leiomyosarcoma from leiomyoma. Uterine leiomyosarcoma tended to have lower ovarian steroid receptors immunoreactivity rates than leiomyoma. Leiomyoma tended to have a higher quantity of intratumoral mast cells than leiomyosarcoma, while the expression of proliferating cell nuclear antigen was lower in them. Conclusion: Because the estimation of mitotic count was subject to significant variation, the immunohistochemical expression of ovarian steroid receptors, mast cells and proliferating cell nuclear antigen seemed to be helpful for the discrimination of unusual leiomyoma from leiomyosarcoma.